Time Matters: ENS debate on early treatment and early switching

Early switching; how important is it? Time matters; time is brain. #MSBlog #MSResearch

"The following are my slides from yesterday's debate."

Monday, June 10, 2013, Plenary Hall 11:45 – 13:15

Novartis Satellite Symposium: Time matters: early and enduring treatment options in MS

11:45 – 12:10 MS pathology: inflammation and neurodegeneration Chair: Montalban (Barcelona, ES)
12:10 – 12:35 Treatment decisions debate: early vs. late switching. B. Kieseier, G. Giovannoni (Düsseldorf, DE; London, GB)
12:35 – 13:15 Panel discussion: when to switch treatment, T. Vollmer (Colorado, US)



"Several very challenging questions came up during the question time that need to be readdressed on this blog. For example, what is benign disease? I personally don't think you make a call on benign disease until the MSer concerned has had the disease for 25 or 30 years. Simply labelling someone as having MS is non-benign. Should we be denying people early active treatment because we may be treating a few MSers who will turn out to have benign disease 20 years later. More on this another time."

CoI: multiple

Labels: , , ,